Brief: OncoSec Enters Into Agreement With Merck For Pivotal Global Phase 3 Study, Keynote-C87, Of Tavo Combined With Keytruda

OncoSec Medical Incorporated

06/07/2021 21:04

July 6 (Reuters) - OncoSec Medical Inc  ONCS.O :
    * ONCOSEC ENTERS INTO A COLLABORATION AGREEMENT WITH MERCK
FOR A
PIVOTAL GLOBAL PHASE 3 STUDY, KEYNOTE-C87, OF TAVO™ COMBINED
WITH KEYTRUDA® FOR LATE-STAGE METASTATIC MELANOMA
    * ONCOSEC MEDICAL INC - KEYNOTE-C87 INTENDS TO ENROLL
APPROXIMATELY 400 PATIENTS AND IS PLANNED TO BE CONDUCTED IN
U.S., CANADA, EU, AND AUSTRALIA
    * ONCOSEC MEDICAL INC - UNDER TERMS OF AGREEMENT, MERCK WILL
PROVIDE KEYTRUDA , WHILE ONCOSEC WILL PROVIDE INVESTIGATIONAL
DRUG, TAVO
    * ONCOSEC MEDICAL INC - EACH PARTY WILL BE RESPONSIBLE FOR
ITS OWN
INTERNAL COSTS, WITH ONCOSEC COVERING THIRD PARTY COSTS
    * ONCOSEC MEDICAL INC - KEYNOTE-C87 IS INTENDED TO SUPPORT
ACCELERATED APPROVAL BY U.S. FDA AND/OR SERVE AS A PIVOTAL STUDY
TO SUPPORT A FULL LICENSURE

Source text for Eikon:  ID:nPn1Ns9g5a 
Further company coverage:  ONCS.O 

 ((Reuters.Briefs@thomsonreuters.com;))